JP2007518673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007518673A5 JP2007518673A5 JP2006516814A JP2006516814A JP2007518673A5 JP 2007518673 A5 JP2007518673 A5 JP 2007518673A5 JP 2006516814 A JP2006516814 A JP 2006516814A JP 2006516814 A JP2006516814 A JP 2006516814A JP 2007518673 A5 JP2007518673 A5 JP 2007518673A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- aryl
- alkoxy
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 21
- -1 Nitro, amino Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000001475 halogen functional group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 7
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 7
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 7
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 150000003573 thiols Chemical class 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 5
- XKCJYMCNPFBMQW-UHFFFAOYSA-N cyano(nitramido)cyanamide Chemical compound [O-][N+](=O)NN(C#N)C#N XKCJYMCNPFBMQW-UHFFFAOYSA-N 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 150000001356 alkyl thiols Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000005504 styryl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- IJIUZCQWOQWQJS-UHFFFAOYSA-N 3-amino-1-(2-aminophenyl)-2-(2,4-dinitrophenyl)propan-1-one Chemical compound C=1C=C([N+]([O-])=O)C=C([N+]([O-])=O)C=1C(CN)C(=O)C1=CC=CC=C1N IJIUZCQWOQWQJS-UHFFFAOYSA-N 0.000 claims 1
- KWFKLGMSYQFQLQ-UHFFFAOYSA-N 4-(2-aminophenyl)-2-(2,4-dinitroanilino)-4-oxobutanoic acid Chemical compound NC1=CC=CC=C1C(=O)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O KWFKLGMSYQFQLQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 238000003975 animal breeding Methods 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003280 chronobiological effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000008451 emotion Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002461 excitatory amino acid Effects 0.000 claims 1
- 239000003257 excitatory amino acid Substances 0.000 claims 1
- 208000031424 hyperprolactinemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 208000006155 precocious puberty Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15666903A IL156669A0 (en) | 2003-06-26 | 2003-06-26 | 2-aminobenzoyl derivatives |
| PCT/IL2004/000567 WO2004112690A2 (en) | 2003-06-26 | 2004-06-24 | 2-aminobenzoyl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007518673A JP2007518673A (ja) | 2007-07-12 |
| JP2007518673A5 true JP2007518673A5 (enExample) | 2007-08-23 |
| JP4646907B2 JP4646907B2 (ja) | 2011-03-09 |
Family
ID=32587677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516814A Expired - Fee Related JP4646907B2 (ja) | 2003-06-26 | 2004-06-24 | ２−アミノベンゾイル誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8309767B2 (enExample) |
| EP (1) | EP1644316B1 (enExample) |
| JP (1) | JP4646907B2 (enExample) |
| KR (1) | KR101115196B1 (enExample) |
| CN (1) | CN1835910B (enExample) |
| AR (1) | AR044786A1 (enExample) |
| AT (1) | ATE460391T1 (enExample) |
| AU (1) | AU2004249012B2 (enExample) |
| BR (1) | BRPI0411382A (enExample) |
| CA (1) | CA2527112C (enExample) |
| CY (1) | CY1110043T1 (enExample) |
| DE (1) | DE602004025937D1 (enExample) |
| DK (1) | DK1644316T3 (enExample) |
| EA (1) | EA011255B1 (enExample) |
| ES (1) | ES2341958T3 (enExample) |
| HN (1) | HN2004000224A (enExample) |
| IL (1) | IL156669A0 (enExample) |
| IS (1) | IS8235A (enExample) |
| MX (1) | MXPA06000022A (enExample) |
| NO (1) | NO20060420L (enExample) |
| NZ (1) | NZ544908A (enExample) |
| PA (1) | PA8605401A1 (enExample) |
| PE (1) | PE20050230A1 (enExample) |
| PL (1) | PL1644316T3 (enExample) |
| PT (1) | PT1644316E (enExample) |
| SI (1) | SI1644316T1 (enExample) |
| TW (1) | TWI342210B (enExample) |
| UA (1) | UA85187C2 (enExample) |
| UY (1) | UY28382A1 (enExample) |
| WO (1) | WO2004112690A2 (enExample) |
| ZA (1) | ZA200600640B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1869002A (zh) | 2005-05-27 | 2006-11-29 | 中国科学院上海药物研究所 | 一类非甾体雄激素受体调节剂、其制备方法和用途 |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| JP6664814B2 (ja) * | 2014-08-18 | 2020-03-13 | 国立大学法人大阪大学 | 新規２−アミノベンゾイル誘導体 |
| JP6836044B2 (ja) * | 2015-03-05 | 2021-02-24 | 国立大学法人 東京医科歯科大学 | 長期記憶誘導剤 |
| US11712425B2 (en) | 2018-03-14 | 2023-08-01 | Albert Einstein College Of Medicine | Immunoregulatory role of 3-OH-kynurenamine and uses thereof |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT305987B (de) | 1969-12-18 | 1973-03-26 | Degussa | Verfahren zur Herstellung von neuen Aminoketonen |
| GB1334884A (en) * | 1970-12-18 | 1973-10-24 | Sumitomo Chemical Co | Aminoalcohols and their conversion to aminoketones |
| JPS5336455B2 (enExample) * | 1973-02-03 | 1978-10-03 | ||
| US4018823A (en) * | 1976-04-20 | 1977-04-19 | Morton-Norwich Products, Inc. | 4',5'-Dimethoxy-2',3-diaminopropiophenone dihydrochloride |
| FR2569185B1 (fr) | 1984-08-20 | 1986-09-05 | Lafon Labor | Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique |
-
2003
- 2003-06-26 IL IL15666903A patent/IL156669A0/xx not_active IP Right Cessation
-
2004
- 2004-06-16 AR ARP040102095A patent/AR044786A1/es not_active Application Discontinuation
- 2004-06-18 PE PE2004000604A patent/PE20050230A1/es not_active Application Discontinuation
- 2004-06-22 PA PA20048605401A patent/PA8605401A1/es unknown
- 2004-06-23 UY UY28382A patent/UY28382A1/es not_active Application Discontinuation
- 2004-06-24 BR BRPI0411382-9A patent/BRPI0411382A/pt not_active IP Right Cessation
- 2004-06-24 PT PT04744907T patent/PT1644316E/pt unknown
- 2004-06-24 MX MXPA06000022A patent/MXPA06000022A/es active IP Right Grant
- 2004-06-24 DK DK04744907.9T patent/DK1644316T3/da active
- 2004-06-24 TW TW093118235A patent/TWI342210B/zh not_active IP Right Cessation
- 2004-06-24 WO PCT/IL2004/000567 patent/WO2004112690A2/en not_active Ceased
- 2004-06-24 AT AT04744907T patent/ATE460391T1/de not_active IP Right Cessation
- 2004-06-24 HN HN2004000224A patent/HN2004000224A/es unknown
- 2004-06-24 ZA ZA200600640A patent/ZA200600640B/en unknown
- 2004-06-24 DE DE602004025937T patent/DE602004025937D1/de not_active Expired - Lifetime
- 2004-06-24 UA UAA200600303A patent/UA85187C2/ru unknown
- 2004-06-24 AU AU2004249012A patent/AU2004249012B2/en not_active Ceased
- 2004-06-24 US US10/562,197 patent/US8309767B2/en not_active Expired - Fee Related
- 2004-06-24 EA EA200600115A patent/EA011255B1/ru not_active IP Right Cessation
- 2004-06-24 SI SI200431416T patent/SI1644316T1/sl unknown
- 2004-06-24 CA CA2527112A patent/CA2527112C/en not_active Expired - Fee Related
- 2004-06-24 CN CN200480017943XA patent/CN1835910B/zh not_active Expired - Fee Related
- 2004-06-24 EP EP04744907A patent/EP1644316B1/en not_active Expired - Lifetime
- 2004-06-24 JP JP2006516814A patent/JP4646907B2/ja not_active Expired - Fee Related
- 2004-06-24 ES ES04744907T patent/ES2341958T3/es not_active Expired - Lifetime
- 2004-06-24 KR KR1020057025006A patent/KR101115196B1/ko not_active Expired - Fee Related
- 2004-06-24 NZ NZ544908A patent/NZ544908A/en unknown
- 2004-06-24 PL PL04744907T patent/PL1644316T3/pl unknown
-
2006
- 2006-01-16 IS IS8235A patent/IS8235A/is unknown
- 2006-01-25 NO NO20060420A patent/NO20060420L/no not_active Application Discontinuation
-
2010
- 2010-05-25 CY CY20101100463T patent/CY1110043T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200522952A (en) | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors | |
| JP2000256194A (ja) | 核内レセプタ作動薬およびその効果増強剤 | |
| JP2009526831A5 (enExample) | ||
| US20100256367A1 (en) | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | |
| JP2007518673A5 (enExample) | ||
| TWI869568B (zh) | 新穎之氫醌衍生物 | |
| JP2003526663A (ja) | Ｃｏｍｔ阻害剤の鎮痛剤としての用途 | |
| WO2002045750A1 (en) | Combination drugs | |
| JP4646907B2 (ja) | ２−アミノベンゾイル誘導体 | |
| CN114853686B (zh) | 三氮唑酮类化合物及其医药用途 | |
| US6107316A (en) | Method for treating protozoal infections | |
| US11807604B1 (en) | Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders | |
| US20060241084A1 (en) | Inhibition of vascular endothelial growth factor | |
| JP6761347B2 (ja) | 脂質異常症治療剤 | |
| JP2023002841A (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| JP2003512425A (ja) | ６−メトキシ−２−ナフチル酢酸プロドラッグ | |
| JP2004099493A (ja) | ４−［６−［ｎ−イソブチル−ｎ−（４−メチル−２−チアゾリルスルフォニル）アミノ］インダン−５−イルオキシメチル］安息香酸の新規結晶、その製造方法およびそれを有効成分として含有する薬剤 | |
| WO2022155290A1 (en) | Antibiotics with improved drug resistance profile | |
| HK1094795B (en) | 2-aminobenzoyl derivatives | |
| JPWO2000053563A1 (ja) | 核内リセプターｐｐａｒの新規リガンド | |
| MXPA98003443A (en) | Method for the treatment of protozoi infections | |
| FR2919803A1 (fr) | Utilisation d'un antagoniste non peptidique du recepteur b1 pour la preparation de medicaments utiles pour le traitement de l'obesite et des pathologies liees a l'obesite ou au diabete |